Glenmark starts selling pain killer drugs in US

10 November 2008

Mumbai: Glenmark Pharmaceutical's US subsidiary Glenmark Generics has launched morphine sulfate oral concentrate solution in the US, its fifth product in the painkiller category to be sold in the US.

Glenmark will market the product through a licensing agreement with a US-based pharmaceutical development company, according to a filing with the Bombay Stock Exchange.

Morphine sulfate oral concentrate solution20mg/ml is offered in three presentations and is indicated for the relief of moderate to severe pain.

Morphine sulfate oral concentrate solution had total sales in excess of $15 million for the 12 month period ended June 2008, according to IMS Health.

This product launch complements Glenmark's established portfolio of both oral solid and oral liquid pain management products.

''This niche market category maintains a high barrier to entry due to strict DEA regulations thereby limiting the number of competitor companies and showcasing Glenmark as the sole India-based company in each of their product launches'', the company said.